{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T19:14:49Z","timestamp":1783451689072,"version":"3.55.0"},"reference-count":50,"publisher":"Bioscientifica","issue":"1","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":183,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,1]]},"abstract":"<jats:p>Androgen deprivation therapy (ADT) is regularly used to treat locally advanced and metastatic prostate cancer (PCa) with toxicities, including metabolic syndrome (MS) and associated adverse hormonal changes. This study evaluated whether metformin mitigates changes in laboratory biomarkers associated with MS and type II diabetes mellitus (T2DM) in PCa patients receiving ADT. PRIME is a phase III double-blind, randomized controlled trial in which 166 normoglycemic patients with PCa receiving ADT were randomized to receive metformin or placebo. For this study, 47 patients from the metformin arm and 32 patients from the placebo arm underwent serum collection and analysis of the following analytes at baseline, 9, and 12 months: IGF-1, IGFBP1, IGFBP2, IGFBP3, IGFBP7, leptin, adiponectin, GDF15, insulin, C-peptide, GIP, GLP-1, and IL-6. Independent t-tests were used to determine whether significant changes in analytes were evident in patients receiving metformin vs placebo and to evaluate analyte changes from baseline for the metformin and placebo groups separately. Mean leptin values increased markedly in the placebo group and significantly less in the metformin group across all time points. Significant improvements were also observed in IGFBP1, IL-6, C-peptide, and GLP-1 with metformin compared with placebo. GDF15 and IGFBP3 significantly increased compared with baseline with ADT alone. This study demonstrates that metformin can mitigate biomarker changes induced by ADT associated with an increased risk of T2DM and MS. In addition, the attenuated increase in leptin signals a potential for improved PCa outcomes, as high leptin values have been correlated with aggressive disease and worse prognosis.<\/jats:p>","DOI":"10.1530\/eo-25-0114","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T12:01:30Z","timestamp":1781697690000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-15","source":"Crossref","is-referenced-by-count":0,"title":["Metformin modifies hormone changes associated with androgen deprivation therapy for prostate cancer"],"prefix":"10.1530","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-8522-5908","authenticated-orcid":true,"given":"Mathew","family":"Gorman","sequence":"first","affiliation":[{"name":"1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nawaid","family":"Usmani","sequence":"additional","affiliation":[{"name":"1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael N","family":"Pollak","sequence":"additional","affiliation":[{"name":"2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunita","family":"Ghosh","sequence":"additional","affiliation":[{"name":"1"},{"name":"3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Elangovan","sequence":"additional","affiliation":[{"name":"4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Kim","sequence":"additional","affiliation":[{"name":"5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Thoms","sequence":"additional","affiliation":[{"name":"6"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Bouchard","sequence":"additional","affiliation":[{"name":"7"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Peacock","sequence":"additional","affiliation":[{"name":"8"},{"name":"9"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Wang","sequence":"additional","affiliation":[{"name":"10"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil E","family":"Fleshner","sequence":"additional","affiliation":[{"name":"11"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Campbell","sequence":"additional","affiliation":[{"name":"12"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Vigneault","sequence":"additional","affiliation":[{"name":"13"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Vincent","sequence":"additional","affiliation":[{"name":"14"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"So","sequence":"additional","affiliation":[{"name":"8"},{"name":"9"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio L","family":"Cury","sequence":"additional","affiliation":[{"name":"15"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harvey C","family":"Quon","sequence":"additional","affiliation":[{"name":"16"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Ryan G","family":"Carlson","sequence":"additional","affiliation":[{"name":"17"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Lambert","sequence":"additional","affiliation":[{"name":"18"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Klotz","sequence":"additional","affiliation":[{"name":"19"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Chi","sequence":"additional","affiliation":[{"name":"8"},{"name":"9"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Brundage","sequence":"additional","affiliation":[{"name":"20"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry S","family":"Courneya","sequence":"additional","affiliation":[{"name":"1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard J","family":"Eigl","sequence":"additional","affiliation":[{"name":"8"},{"name":"9"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"2026070714140408600_bib1","doi-asserted-by":"crossref","first-page":"e0117344","DOI":"10.1371\/journal.pone.0117344","article-title":"Quantifying the evidence for the risk of metabolic syndrome and its components following androgen deprivation therapy for prostate cancer: a meta-analysis","volume":"10","author":"Bosco","year":"2015","journal-title":"PLoS One"},{"key":"2026070714140408600_bib2","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.eururo.2022.08.002","article-title":"Androgen receptor signaling inhibitors in addition to docetaxel with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis","volume":"82","author":"Yanagisawa","year":"2022","journal-title":"Eur Urol"},{"key":"2026070714140408600_bib3","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ijrobp.2017.02.004","article-title":"Duration of androgen deprivation in locally advanced prostate cancer: long-term update of NRG oncology RTOG 9202","volume":"98","author":"Lawton","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026070714140408600_bib4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.eururo.2011.08.026","article-title":"Contemporary role of androgen deprivation therapy for prostate cancer","volume":"61","author":"Pagliarulo","year":"2012","journal-title":"Eur Urol"},{"key":"2026070714140408600_bib5","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/cncr.21642","article-title":"Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy","volume":"106","author":"Basaria","year":"2006","journal-title":"Cancer"},{"key":"2026070714140408600_bib6","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1016\/j.juro.2014.12.027","article-title":"Risk of diabetes among patients receiving primary androgen deprivation therapy for clinically localized prostate cancer","volume":"193","author":"Tsai","year":"2015","journal-title":"J Urol"},{"key":"2026070714140408600_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/820403","article-title":"The prevalence of cardiac risk factors in men with localized prostate cancer undergoing androgen deprivation therapy in British Columbia, Canada","volume":"2015","author":"Davis","year":"2015","journal-title":"J Oncol"},{"key":"2026070714140408600_bib8","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1200\/JCO.2006.06.2497","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer","volume":"24","author":"Keating","year":"2006","journal-title":"J Clin Oncol"},{"key":"2026070714140408600_bib9","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.2337\/dci22-0034","article-title":"Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of diabetes (EASD)","volume":"45","author":"Davies","year":"2022","journal-title":"Diabetes Care"},{"key":"2026070714140408600_bib10","doi-asserted-by":"crossref","first-page":"601","DOI":"10.2337\/dc18-1970","article-title":"Long-term effects of metformin on diabetes prevention: identification of subgroups that benefited most in the diabetes prevention program and diabetes prevention program outcomes study","volume":"42","author":"Diabetes Prevention Program Research Group","year":"2019","journal-title":"Diabetes Care"},{"key":"2026070714140408600_bib11","doi-asserted-by":"crossref","first-page":"446","DOI":"10.2337\/dc11-1465","article-title":"Quantifying the effect of metformin treatment and dose on glycemic control","volume":"35","author":"Hirst","year":"2012","journal-title":"Diabetes Care"},{"key":"2026070714140408600_bib12","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.2337\/dc12-0719","article-title":"Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease","volume":"36","author":"Hong","year":"2013","journal-title":"Diabetes Care"},{"key":"2026070714140408600_bib13","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","article-title":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet"},{"key":"2026070714140408600_bib14","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/JU.0000000000004695","article-title":"A randomized phase 3 trial of metformin in patients initiating androgen deprivation therapy as prevention and intervention of metabolic syndrome: the PRIME study","volume":"214","author":"Eigl","year":"2025","journal-title":"J Urol"},{"key":"2026070714140408600_bib15","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/aje\/kwv188","article-title":"Insulin-like growth factor 1 and insulin-like growth factor-binding protein 3 in relation to the risk of type 2 diabetes mellitus: results from the EPIC-potsdam study","volume":"183","author":"Drogan","year":"2016","journal-title":"Am J Epidemiol"},{"key":"2026070714140408600_bib16","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.2337\/db11-1488","article-title":"Insulin-like growth factor axis and risk of type 2 diabetes in women","volume":"61","author":"Rajpathak","year":"2012","journal-title":"Diabetes"},{"key":"2026070714140408600_bib17","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1111\/jgs.13390","article-title":"Changes in insulin-like growth factor-I and its binding proteins are associated with diabetes mellitus in older adults","volume":"63","author":"Aneke-Nash","year":"2015","journal-title":"J Am Geriatr Soc"},{"key":"2026070714140408600_bib18","article-title":"Serum IGFBP7 levels associate with insulin resistance and the risk of metabolic syndrome in a Chinese population","volume":"5","author":"Liu","year":"2015","journal-title":"Sci Rep"},{"key":"2026070714140408600_bib19","doi-asserted-by":"crossref","first-page":"e31006","DOI":"10.1097\/MD.0000000000031006","article-title":"Association of serum leptin and insulin levels among type 2 diabetes mellitus patients: a case-control study","volume":"101","author":"Zhao","year":"2022","journal-title":"Medicine"},{"key":"2026070714140408600_bib20","doi-asserted-by":"crossref","first-page":"12668","DOI":"10.3390\/ijms252312668","article-title":"Increased leptin levels in plasma and serum in patients with metabolic disorders: a systematic review and meta-analysis","volume":"25","author":"Hern\u00e1ndez-D\u00edaz","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2026070714140408600_bib21","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1210\/jc.2017-02085","article-title":"Relationship between 12 adipocytokines and distinct components of the metabolic syndrome","volume":"103","author":"Ebert","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070714140408600_bib22","doi-asserted-by":"crossref","first-page":"881","DOI":"10.3390\/ijms25020881","article-title":"Relationships between circulating biomarkers and body composition parameters in patients with metabolic syndrome: a community-based study","volume":"25","author":"Tarabeih","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2026070714140408600_bib23","doi-asserted-by":"crossref","first-page":"e0132244","DOI":"10.1371\/journal.pone.0132244","article-title":"Glycated hemoglobin, fasting insulin and the metabolic syndrome in males. Cross-sectional analyses of the aragon workers health study baseline","volume":"10","author":"Saravia","year":"2015","journal-title":"PLoS One"},{"key":"2026070714140408600_bib24","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/1475-2840-10-108","article-title":"Elevated fasting insulin predicts the future incidence of metabolic syndrome: a 5-year follow-up study","volume":"10","author":"Sung","year":"2011","journal-title":"Cardiovasc Diabetol"},{"key":"2026070714140408600_bib25","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.3390\/jcm9093001","article-title":"Plasma c-peptide and risk of developing type 2 diabetes in the general population","volume":"9","author":"Sokooti","year":"2020","journal-title":"J Clin Med"},{"key":"2026070714140408600_bib26","doi-asserted-by":"crossref","first-page":"921","DOI":"10.2174\/187152711799219271","article-title":"C-Peptide and its correlation to parameters of insulin resistance in the metabolic syndrome","volume":"10","author":"Banu","year":"2012","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"2026070714140408600_bib27","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1475-2840-9-17","article-title":"Elevated circulating levels of an incretin hormone, glucagon-like peptide-1, are associated with metabolic components in high-risk patients with cardiovascular disease","volume":"9","author":"Yamaoka-Tojo","year":"2010","journal-title":"Cardiovasc Diabetol"},{"key":"2026070714140408600_bib28","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1530\/EJE-11-0765","article-title":"Elevated plasma glucose-dependent insulinotropic polypeptide associates with hyperinsulinemia in metabolic syndrome","volume":"166","author":"Calanna","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"2026070714140408600_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.103062","article-title":"Meta-analysis investigating the role of interleukin-6 mediated inflammation in type 2 diabetes","volume":"61","author":"Bowker","year":"2020","journal-title":"EBioMedicine"},{"key":"2026070714140408600_bib30","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.metabol.2013.01.019","article-title":"Components of the Interleukin-6 transsignalling system are associated with the metabolic syndrome, endothelial dysfunction and arterial stiffness","volume":"62","author":"Weiss","year":"2013","journal-title":"Metabolism"},{"key":"2026070714140408600_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2024.111615","article-title":"The association between interleukin family and diabetes mellitus and its complications: an overview of systematic reviews and meta-analyses","volume":"210","author":"Jin","year":"2024","journal-title":"Diabetes Res Clin Pract"},{"key":"2026070714140408600_bib32","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1111\/jog.15942","article-title":"The association between leptin and diabetes: a meta-analysis","volume":"50","author":"Wu","year":"2024","journal-title":"J Obstet Gynaecol Res"},{"key":"2026070714140408600_bib33","doi-asserted-by":"crossref","first-page":"5687","DOI":"10.1002\/cam4.3082","article-title":"Assessment of expression levels of leptin and leptin receptor as potential biomarkers for risk of prostate cancer development and aggressiveness","volume":"9","author":"Kamel","year":"2020","journal-title":"Cancer Med"},{"key":"2026070714140408600_bib34","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.3892\/ijo.2015.2845","article-title":"Long-term exposure to leptin enhances the growth of prostate cancer cells","volume":"46","author":"Noda","year":"2015","journal-title":"Int J Oncol"},{"key":"2026070714140408600_bib35","doi-asserted-by":"crossref","first-page":"81049","DOI":"10.18632\/oncotarget.12747","article-title":"Genetic polymorphisms in leptin, adiponectin and their receptors affect risk and aggressiveness of prostate cancer: evidence from a meta-analysis and pooled-review","volume":"7","author":"Hu","year":"2016","journal-title":"Oncotarget"},{"key":"2026070714140408600_bib36","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-79345-4","article-title":"Circulating adiponectin and leptin and risk of overall and aggressive prostate cancer: a systematic review and meta-analysis","volume":"11","author":"Burton","year":"2021","journal-title":"Sci Rep"},{"key":"2026070714140408600_bib37","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1530\/ERC-20-0405","article-title":"Leptin antagonism inhibits prostate cancer xenograft growth and progression","volume":"28","author":"Philp","year":"2021","journal-title":"Endocr Relat Cancer"},{"key":"2026070714140408600_bib38","first-page":"520","article-title":"Relationships of body composition and adipocytokines with outcomes in metastatic castration-resistant prostate cancer patients receiving docetaxel chemotherapy","volume":"25","author":"Li","year":"2023","journal-title":"Asian J Androl"},{"key":"2026070714140408600_bib39","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(25)00231-1","article-title":"Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol","volume":"26","author":"Gillessen","year":"2025","journal-title":"Lancet Oncol"},{"key":"2026070714140408600_bib40","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA5002","article-title":"A randomized, double-blind, placebo-controlled trial of metformin in reducing progression among men on expectant management for low-risk prostate cancer: The MAST (Metformin Active Surveillance Trial) study","volume":"42","author":"Fleshner","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026070714140408600_bib41","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/s41574-018-0016-2","article-title":"Glucagon-like peptide 1 in health and disease","volume":"14","author":"Andersen","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"2026070714140408600_bib42","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.2337\/db13-1169","article-title":"Exendin-4, a GLP-1 receptor agonist, attenuates prostate cancer growth","volume":"63","author":"Nomiyama","year":"2014","journal-title":"Diabetes"},{"key":"2026070714140408600_bib43","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-25-0185","article-title":"GLP1 receptor agonism alters growth and therapeutic response in prostate cancer","volume":"32","author":"Bera","year":"2025","journal-title":"Endocr Relat Cancer"},{"key":"2026070714140408600_bib44","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1007\/s00125-023-05972-x","article-title":"Potential preventive properties of GLP-1 receptor agonists against prostate cancer: a nationwide cohort study","volume":"66","author":"Skriver","year":"2023","journal-title":"Diabetologia"},{"key":"2026070714140408600_bib45","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/biof.1871","article-title":"Growth differentiation factor-15 is independently associated with metabolic syndrome and hyperglycemia in non-elderly subjects","volume":"49","author":"Ho","year":"2023","journal-title":"Biofactors"},{"key":"2026070714140408600_bib46","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-23-0241","article-title":"IGF-1 axis changes with ADT and docetaxel in metastatic prostate cancer","volume":"30","author":"Ravi","year":"2023","journal-title":"Endocr Relat Cancer"},{"key":"2026070714140408600_bib47","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2018.01238","article-title":"Meta-analysis of adiponectin as a biomarker for the detection of metabolic syndrome","volume":"9","author":"Liu","year":"2018","journal-title":"Front Physiol"},{"key":"2026070714140408600_bib48","doi-asserted-by":"crossref","first-page":"e060377","DOI":"10.1136\/bmjopen-2021-060377","article-title":"Association between adiponectin and newly diagnosed type 2 diabetes in population with the clustering of obesity, dyslipidaemia and hypertension: a cross-sectional study","volume":"13","author":"Hong","year":"2023","journal-title":"BMJ Open"},{"key":"2026070714140408600_bib49","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.urology.2007.08.035","article-title":"Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer","volume":"71","author":"Smith","year":"2008","journal-title":"Urology"},{"key":"2026070714140408600_bib50","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/j.1939-4640.2005.tb02876.x","article-title":"Testosterone administration suppresses adiponectin levels in men","volume":"26","author":"Page","year":"2005","journal-title":"J Androl"}],"container-title":["Endocrine Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eo.bioscientifica.com\/view\/journals\/eo\/6\/1\/EO-25-0114.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eo.bioscientifica.com\/downloadpdf\/journals\/eo\/6\/1\/EO-25-0114.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/eo\/article-pdf\/doi\/10.1530\/EO-25-0114\/520162\/eo-25-0114.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/eo\/article-pdf\/doi\/10.1530\/EO-25-0114\/520162\/eo-25-0114.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T18:14:14Z","timestamp":1783448054000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/eo\/article\/6\/1\/e250114\/77613\/Metformin-modifies-hormone-changes-associated-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,1]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,1]]}},"URL":"https:\/\/doi.org\/10.1530\/eo-25-0114","relation":{},"ISSN":["2634-4793"],"issn-type":[{"value":"2634-4793","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,1]]},"article-number":"e250114"}}